시장보고서

상품코드

1555504

구강붕해정 시장 : 부문별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율, 예측(2024-2032년)

Orally Disintegrating Tablet Market, By Drug Type, By Indication, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

발행일: 2024년 08월 | 리서치사:

AnalystView Market Insights | 페이지 정보: 영문 390 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

보고서 하이라이트

구강붕해정(Orally Disintegrating Tablet) 시장 규모는 2023년 131억 2,312만 달러였으며, 2024년부터 2032년까지 CAGR 8.1%로 추이하며 확대 될 것으로 예상

구강붕해정 시장-시장 역학

바이오 가용성 향상과 편의성 향상이 시장 수요를 촉진할 전망

ODT는 특정 약제의 생체이용률을 향상시키고 보다 효과적으로 만들 수 있습니다. 이는 신속한 작용 발현을 필요로 하는 약제에 특히 유용합니다. ODT는 소아 및 노인 의료뿐만 아니라 정신 건강, 알레르기, 통증 관리 등 다양한 치료 분야에서 사용되고 있습니다. 이러한 광범위한 용도가 시장 성장을 뒷받침하고 있습니다. 기존의 정제보다 ODT가 사용하기 쉽고 물이 필요하지 않기 때문에 환자는 ODT를 선호합니다. 환자의 컴플라이언스가 향상되면 치료 성적도 향상되고 나아가 수요도 높아집니다.

또한 ODT는 기존의 정제와 캡슐을 삼키기가 어려운 환자에게 실용적인 솔루션입니다. 여기에는 소아, 노인 및 특정 병리학을 가진 환자가 포함됩니다. 물이 필요없는 투여의 용이성은 환자의 컴플라이언스 향상에 기여합니다. 정제 제제 기술의 혁신으로 ODT의 맛, 안정성 및 효능이 향상되었습니다. 제조 공정의 진보는 보다 효과적이고 환자 친화적인 ODT를 가능하게 했습니다.

구강붕해정 시장-주요 인사이트

리서치 애널리스트 분석에 따르면 세계 시장은 예측 기간(2024-2032년) 동안 약 8.1%의 CAGR로 매년 성장할 것으로 추정됩니다.

약제 유형별 세분화에 따르면, 알레르기 질환 증가로 인해 항알레르기 약제 부문은 2023년에 가장 큰 시장 점유율을 나타낼 것으로 예측됩니다.

적응증별로는 심혈관 치료에 있어서 ODT의 막대한 수요로부터, 심혈관 질환 분야가 2023년의 주요 적응증이었습니다.

유통 채널별로는 병원에서 ODT 수요가 높기 때문에 병원 약국이 2023년 유통 채널의 톱이었습니다.

지역별로는 만성질환의 유병률 증가로 북미가 2023년 가장 많은 수익을 창출했습니다.

구강붕해정 시장-세분화 분석 :

구강붕해정 세계 시장은 약제 유형, 적응증, 유통 채널, 지역에 따라 세분화됩니다.

의약품 유형별로는 항정신병제, 항간질제, 항고혈압제, 항불안제, 항알레르기제, 양성자 펌프 억제제 등 7가지로 분류됩니다. 시장을 독점하는 것은 항 알레르기 약제입니다. 알레르기 질환의 유병률이 높아 항알레르기 정제 수요가 증가하고 있습니다.

시장은 적응증별로 신경 질환, 심혈관질환, 소화기질환, 알레르기질환 등 5가지로 분류됩니다. 심혈관 질환 분야가 시장을 독점하고 있습니다. ODT는 모든 심혈관 질환의 치료에 널리 사용되며, 이는 이 분야의 성장을 뒷받침하고 있습니다.

시장은 유통 채널에 따라 병원 약국, 온라인 약국 및 기타 세 가지로 분류됩니다. 병원 약국 분야는 시장을 독점하고 있으며 예측 기간 동안에도 높은 우위를 유지할 것으로 예상됩니다. 온라인 약국 부문은 예측 기간 동안 가장 빠른 속도로 성장할 것으로 예측됩니다.

구강붕해정 시장 : 지역별 인사이트

지역적으로는 북미, 남미, 유럽, 아시아 태평양, 중동 및 아프리카의 각 지역으로 퍼져 있습니다. 북미는 ODT 세계 시장에서 큰 점유율을 차지하고 있으며, 그 주된 이유는 고급 건강 관리 인프라와 만성 질환의 높은 유병률에 있습니다. 아시아 태평양은 건강 관리 접근성이 향상되고 만성 질환의 유병률이 증가하고 환자 인구가 많기 때문에 ODT 시장이 급성장하고 있습니다. 인도와 중국과 같은 국가에서는 높은 인구 밀도와 의료 요구가 증가함에 따라 시장 기회가 커지고 있습니다. 또한 국내 제약회사가 ODT 제제를 개발하는 동향도 높아지고 있습니다.

구강붕해정 시장-경쟁 구도 :

구강붕해정(ODT) 시장은 경쟁이 치열하여 여러 주요 기업들이 진입하고 있으며 현재 진행 중인 개발이 그 정세를 형성하고 있습니다. 시장 각사는 미각 마스킹을 개선하고 붕괴 시간을 단축한 새로운 ODT 제제를 개발하고 있습니다. 부형제 기술과 정제 매트릭스 설계의 혁신은 환자의 전반적인 사용감을 향상시킵니다. 주요 제약 회사는 아시아 태평양 및 남미와 같은 신흥 시장에서 ODT 제품의 확대에 주력하고 있습니다. 이러한 확대는 건강 관리에 대한 접근이 확대되고 환자에게 친화적인 약제에 대한 수요가 증가하고 있는 것이 배경에 있습니다.

소개
북미
- 개요
- 북미의 주요 제조업체
- 미국
- 캐나다
유럽
- 개요
- 유럽의 주요 제조업체
- 독일
- 이탈리아
- 영국
- 프랑스
- 러시아
- 네덜란드
- 스웨덴
- 폴란드
- 기타
아시아 태평양(APAC)
- 개요
- 아시아 태평양의 주요 제조업체
- 인도
- 중국
- 일본
- 한국
- 호주
- 태국
- 인도네시아
- 필리핀
- 기타
남미
- 개요
- 남미의 주요 제조업체
- 브라질
- 멕시코
- 아르헨티나
- 콜롬비아
- 기타
중동 및 아프리카
- 개요
- 중동 및 아프리카의 주요 제조업체
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 터키
- 알제리
- 이집트
- 기타

제11장 주요 벤더 분석-구강붕해정 산업

경쟁 대시보드
기업 프로파일
- Johnson &Johnson
- Pfizer Inc.
- Novartis AG
- Roche Holding AG
- GlaxoSmithKline(GSK)
- Viatris Inc.
- Aurobindo Pharma
- Teva Pharmaceutical Industries Ltd.
- Zydus Cadilla
- Eli Lilly and Company
- Sanofi
- Boehringer Ingelheim
- AbbVie Inc.
- Amgen Inc.
- Daiichi Sankyo
- MigVax
- Dr. Reddy's Laboratories
- 기타

제12장 애널리스트의 전방위 전망

LYJ

REPORT HIGHLIGHT

Orally Disintegrating Tablet Market size was valued at USD 13,123.12 Million in 2023, expanding at a CAGR of 8.1% from 2024 to 2032.

An Orally Disintegrating Tablet (ODT) is a type of medication that is designed to dissolve quickly in the mouth without needing water. This can be particularly useful for people who have difficulty swallowing traditional tablets or capsules, such as children or elderly patients.

Orally Disintegrating Tablet Market- Market Dynamics

Increasing improved bioavailability and convenience to use are expected to propel market demand

ODTs can enhance the bioavailability of certain drugs, making them more effective. This is particularly beneficial for medications that require rapid onset of action. ODTs are increasingly used in a variety of therapeutic areas beyond just pediatric and geriatric care, including mental health, allergies, and pain management. This broader application helps drive market growth. Patients often prefer ODTs over traditional tablets due to their ease of use and the reduced need for water. Increased patient compliance can lead to better therapeutic outcomes and, subsequently, higher demand.

Furthermore, ODTs offer a practical solution for patients who have difficulty swallowing traditional tablets or capsules. This includes children, elderly individuals, and those with certain medical conditions. The ease of administration without needing water contributes to higher patient compliance. Innovations in tablet formulation technologies have improved the taste, stability, and efficacy of ODTs. Advances in manufacturing processes allow for more effective and patient-friendly ODTs.

Orally Disintegrating Tablet Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 8.1% over the forecast period (2024-2032)

Based on Drug Type segmentation, the anti-allergic drugs segment was predicted to show maximum market share in the year 2023, owing to growing allergic disorders.

Based on Indication segmentation, the cardiovascular diseases segment was the leading Indication in 2023, owing to the high need for ODTs in cardiovascular therapies.

Based on Distribution Channel segmentation, the hospital pharmacies segment was the leading Distribution Channel segment in 2023, owing to the high demand for ODTs in hospitals.

Based on region, North America was the leading revenue generator in 2023, due to the growing prevalence of chronic diseases.

Orally Disintegrating Tablet Market- Segmentation Analysis:

The Global Orally Disintegrating Tablet Market is segmented based on Drug Type, Indication, Distribution Channel, and Region.

The market is divided into seven categories based on Drug Type: anti-psychotics, anti-epileptics, anti-hypertensives, anxiolytics, anti-allergic drugs, proton pump inhibitors, and others. The anti-allergic drugs segment dominates the market. The high prevalence of allergic diseases is growing the demand for anti-allergic tablets.

The market is divided into five categories based on Indication: neurological diseases, cardiovascular diseases, gastrointestinal diseases, allergic diseases, and others. The cardiovascular diseases segment dominates the market. ODTs are widely used for treating every cardiovascular disease which boosts segment growth.

The market is divided into three categories based on Distribution Channels: hospital pharmacies, online pharmacies, and others. The hospital pharmacies segment dominates the market and is expected to maintain its high dominance during the forecast period. The online pharmacies segment is estimated to grow at the fastest rate over the forecast period.

Orally Disintegrating Tablet Market- Geographical Insights

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. North America holds a significant share of the global ODT market, largely due to its advanced healthcare infrastructure and high prevalence of chronic diseases. The Asia-Pacific region is experiencing rapid growth in the ODT market due to rising healthcare access, increasing chronic disease prevalence, and a large patient population. Significant market opportunities in countries like India and China, are driven by high population density and increasing healthcare needs. There is also a growing trend towards domestic pharmaceutical companies developing ODT formulations.

Orally Disintegrating Tablet Market- Competitive Landscape:

The Orally Disintegrating Tablet (ODT) market is highly competitive, with several key players and ongoing developments shaping its landscape. Market players are developing new ODT formulations with improved taste-masking and faster disintegration times. Innovations in excipient technologies and tablet matrix design are enhancing the overall patient experience. Major pharmaceutical companies are focusing on expanding their ODT product offerings in emerging markets such as Asia-Pacific and Latin America. This expansion is driven by growing healthcare access and increasing demand for patient-friendly medication.

Recent Developments:

In March 2023, Zydus Cadilla got FDA approval for manufacturing Olanzapine ODT for nervous system diseases.

In June 2022, Catalent and MigVax announced the utilization of Zydis Bio orally disintegrating tablet technology.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ORALLY DISINTEGRATING TABLET MARKET KEY PLAYERS

Johnson & Johnson
Pfizer Inc.
Novartis AG
Roche Holding AG
GlaxoSmithKline (GSK)
Viatris Inc.
Aurobindo Pharma
Teva Pharmaceutical Industries Ltd.
Zydus Cadilla
Eli Lilly and Company
Sanofi
Boehringer Ingelheim
AbbVie Inc.
Amgen Inc.
Daiichi Sankyo
MigVax
Dr Reddy's Laboratories
Others

GLOBAL ORALLY DISINTEGRATING TABLET MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019-2032

Anti-psychotics
Anti-epileptics
Anti-hypertensives
Anxiolytics
Anti-allergic Drugs
Proton Pump Inhibitors
Others

GLOBAL ORALLY DISINTEGRATING TABLET MARKET, BY INDICATION- MARKET ANALYSIS, 2019-2032

Neurological Diseases
Cardiovascular Diseases
Gastrointestinal Diseases
Allergic Diseases
Others

GLOBAL ORALLY DISINTEGRATING TABLET MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019-2032

Hospital Pharmacies
Online Pharmacies
Others

GLOBAL ORALLY DISINTEGRATING TABLET MARKET, BY REGION- MARKET ANALYSIS, 2019-2032

North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA

1. Orally Disintegrating Tablet Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Orally Disintegrating Tablet Market Snippet by Drug Type
- 2.1.2. Orally Disintegrating Tablet Market Snippet by Indication
- 2.1.3. Orally Disintegrating Tablet Market Snippet by Distribution Channel
- 2.1.4. Orally Disintegrating Tablet Market Snippet by Country
- 2.1.5. Orally Disintegrating Tablet Market Snippet by Region
2.2. Competitive Insights

3. Orally Disintegrating Tablet Key Market Trends

3.1. Orally Disintegrating Tablet Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Orally Disintegrating Tablet Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Orally Disintegrating Tablet Market Opportunities
3.4. Orally Disintegrating Tablet Market Future Trends

4. Orally Disintegrating Tablet Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Orally Disintegrating Tablet Market: COVID-19 Impact Analysis

5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
- 5.2.1. Top Performing Segments
- 5.2.2. Marginal Growth Segments
- 5.2.3. Top Looser Segments
- 5.2.4. Marginal Loss Segments

6. Orally Disintegrating Tablet Market Landscape

6.1. Orally Disintegrating Tablet Market Share Analysis, 2023
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Orally Disintegrating Tablet Market - By Drug Type

7.1. Overview
- 7.1.1. Segment Share Analysis, By Drug Type, 2024 & 2032 (%)
- 7.1.2. Anti-psychotics
- 7.1.3. Anti-epileptics
- 7.1.4. Anti-hypertensives
- 7.1.5. Anxiolytics
- 7.1.6. Anti-allergic Drugs
- 7.1.7. Proton Pump Inhibitors
- 7.1.8. Others

8. Orally Disintegrating Tablet Market - By Indication

8.1. Overview
- 8.1.1. Segment Share Analysis, By Indication, 2024 & 2032 (%)
- 8.1.2. Neurological Diseases
- 8.1.3. Cardiovascular Diseases
- 8.1.4. Gastrointestinal Diseases
- 8.1.5. Allergic Diseases
- 8.1.6. Others

9. Orally Disintegrating Tablet Market - By Distribution Channel

9.1. Overview
- 9.1.1. Segment Share Analysis, By Distribution Channel, 2024 & 2032 (%)
- 9.1.2. Hospital Pharmacies
- 9.1.3. Online Pharmacies
- 9.1.4. Others

10. Orally Disintegrating Tablet Market- By Geography

10.1. Introduction
- 10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
10.2. North America
- 10.2.1. Overview
- 10.2.2. Orally Disintegrating Tablet Key Manufacturers in North America
- 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.2.4. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 10.2.5. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.2.7. U.S.
  - 10.2.7.1. Overview
  - 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.2.7.3. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.2.7.4. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.2.8. Canada
  - 10.2.8.1. Overview
  - 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.2.8.3. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.2.8.4. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3. Europe
- 10.3.1. Overview
- 10.3.2. Orally Disintegrating Tablet Key Manufacturers in Europe
- 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.3.4. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 10.3.5. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.7. Germany
  - 10.3.7.1. Overview
  - 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.7.3. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.3.7.4. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.8. Italy
  - 10.3.8.1. Overview
  - 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.8.3. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.3.8.4. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.3.8.5. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.9. United Kingdom
  - 10.3.9.1. Overview
  - 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.9.3. United Kingdom Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.3.9.4. United Kingdom Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.10. France
  - 10.3.10.1. Overview
  - 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.10.3. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.3.10.4. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.3.10.5. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.11. Russia
  - 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.11.2. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.3.11.3. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.3.11.4. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.12. Netherlands
  - 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.12.2. Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.3.12.3. Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.3.12.4. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.13. Sweden
  - 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.13.2. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.3.13.3. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.14. Poland
  - 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.14.2. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.3.14.3. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.3.14.4. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.15. Rest of Europe
  - 10.3.15.1. Overview
  - 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.15.3. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.3.15.4. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4. Asia Pacific (APAC)
- 10.4.1. Overview
- 10.4.2. Orally Disintegrating Tablet Key Manufacturers in Asia Pacific
- 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.4.4. Asia Pacific Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 10.4.5. Asia Pacific Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.7. India
  - 10.4.7.1. Overview
  - 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.7.3. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.4.7.4. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.8. China
  - 10.4.8.1. Overview
  - 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.8.3. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.4.8.4. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.9. Japan
  - 10.4.9.1. Overview
  - 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.9.3. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.4.9.4. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.10. South Korea
  - 10.4.10.1. Overview
  - 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.10.3. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.4.10.4. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.11. Australia
  - 10.4.11.1. Overview
  - 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.11.3. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.4.11.4. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.12. Thailand
  - 10.4.12.1. Overview
  - 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.12.3. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.4.12.4. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.13. Indonesia
  - 10.4.13.1. Overview
  - 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.13.3. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.4.13.4. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.14. Philippines
  - 10.4.14.1. Overview
  - 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.14.3. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.4.14.4. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.15. Rest of APAC
  - 10.4.15.1. Overview
  - 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.4.15.4. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.5. Latin America
- 10.5.1. Overview
- 10.5.2. Orally Disintegrating Tablet Key Manufacturers in Latin America
- 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.5.4. Latin America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 10.5.5. Latin America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.5.7. Brazil
  - 10.5.7.1. Overview
  - 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.7.3. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.5.7.4. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.5.8. Mexico
  - 10.5.8.1. Overview
  - 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.8.3. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.5.8.4. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.5.9. Argentina
  - 10.5.9.1. Overview
  - 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.9.3. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.5.9.4. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.5.10. Colombia
  - 10.5.10.1. Overview
  - 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.10.3. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.5.10.4. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.5.11. Rest of LATAM
  - 10.5.11.1. Overview
  - 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.5.11.4. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.6. Middle East and Africa
- 10.6.1. Overview
- 10.6.2. Orally Disintegrating Tablet Key Manufacturers in Middle East and Africa
- 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.6.4. Middle East and Africa Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 10.6.5. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.6.7. Saudi Arabia
  - 10.6.7.1. Overview
  - 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.6.7.4. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.6.8. United Arab Emirates
  - 10.6.8.1. Overview
  - 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.8.3. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.6.8.4. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.6.9. Israel
  - 10.6.9.1. Overview
  - 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.9.3. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.6.9.4. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.6.10. Turkey
  - 10.6.10.1. Overview
  - 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.10.3. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.6.10.4. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.6.11. Algeria
  - 10.6.11.1. Overview
  - 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.11.3. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.6.11.4. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.6.12. Egypt
  - 10.6.12.1. Overview
  - 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.12.3. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.6.12.4. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.6.13. Rest of MEA
  - 10.6.13.1. Overview
  - 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.6.13.4. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Orally Disintegrating Tablet Industry

11.1. Competitive Dashboard
11.2. Company Profiles
- 11.2.1. Johnson & Johnson
- 11.2.2. Pfizer Inc.
- 11.2.3. Novartis AG
- 11.2.4. Roche Holding AG
- 11.2.5. GlaxoSmithKline (GSK)
- 11.2.6. Viatris Inc.
- 11.2.7. Aurobindo Pharma
- 11.2.8. Teva Pharmaceutical Industries Ltd.
- 11.2.9. Zydus Cadilla
- 11.2.10. Eli Lilly and Company
- 11.2.11. Sanofi
- 11.2.12. Boehringer Ingelheim
- 11.2.13. AbbVie Inc.
- 11.2.14. Amgen Inc.
- 11.2.15. Daiichi Sankyo
- 11.2.16. MigVax
- 11.2.17. Dr. Reddy's Laboratories
- 11.2.18. Others

12. 360 Degree Analyst View

13. Appendix

13.1. Research Methodology
13.2. References
13.3. Abbreviations
13.4. Disclaimer
13.5. Contact Us